J.P. Morgan Day Three: 2023 Is A Year Of Commercial Challenges

Humira's LOE, Gene Therapy & Alzheimer's Launches Are Major Milestones For 2023

Daily notebook from the J.P. Morgan Healthcare Conference: Gene therapy Vertex enters pricing negotiations on gene therapy, Sanofi sees opportunity in hemophilia despite new gene therapy, and AbbVie raises guidance ahead of the introduction of Humira biosimilars. Plus ICER's Steven Pearson and former Biogen CEO George Scangos weigh in on Alzheimer's developments. 

J.P. Morgan Daily Notebook: Day 3
• Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) president Steven Pearson had positive feedback for Eisai Co., Ltd. on how it communicated the price for its newly approved Alzheimer's medicine Leqembi (lecanemab) to the public, though he said he thinks the $26,500 price set by the company is still too high. ICER is still working on a final assessment, but in the draft assessment ICER determined that Leqembi would be cost effective at an annual list price of $8,500 to $20,600. 

[Sidebar#SC147649]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies